BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2440 related articles for article (PubMed ID: 25957691)

  • 1. Prospective derivation of a living organoid biobank of colorectal cancer patients.
    van de Wetering M; Francies HE; Francis JM; Bounova G; Iorio F; Pronk A; van Houdt W; van Gorp J; Taylor-Weiner A; Kester L; McLaren-Douglas A; Blokker J; Jaksani S; Bartfeld S; Volckman R; van Sluis P; Li VS; Seepo S; Sekhar Pedamallu C; Cibulskis K; Carter SL; McKenna A; Lawrence MS; Lichtenstein L; Stewart C; Koster J; Versteeg R; van Oudenaarden A; Saez-Rodriguez J; Vries RG; Getz G; Wessels L; Stratton MR; McDermott U; Meyerson M; Garnett MJ; Clevers H
    Cell; 2015 May; 161(4):933-45. PubMed ID: 25957691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity.
    Sachs N; de Ligt J; Kopper O; Gogola E; Bounova G; Weeber F; Balgobind AV; Wind K; Gracanin A; Begthel H; Korving J; van Boxtel R; Duarte AA; Lelieveld D; van Hoeck A; Ernst RF; Blokzijl F; Nijman IJ; Hoogstraat M; van de Ven M; Egan DA; Zinzalla V; Moll J; Boj SF; Voest EE; Wessels L; van Diest PJ; Rottenberg S; Vries RGJ; Cuppen E; Clevers H
    Cell; 2018 Jan; 172(1-2):373-386.e10. PubMed ID: 29224780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity.
    Calandrini C; Schutgens F; Oka R; Margaritis T; Candelli T; Mathijsen L; Ammerlaan C; van Ineveld RL; Derakhshan S; de Haan S; Dolman E; Lijnzaad P; Custers L; Begthel H; Kerstens HHD; Visser LL; Rookmaaker M; Verhaar M; Tytgat GAM; Kemmeren P; de Krijger RR; Al-Saadi R; Pritchard-Jones K; Kool M; Rios AC; van den Heuvel-Eibrink MM; Molenaar JJ; van Boxtel R; Holstege FCP; Clevers H; Drost J
    Nat Commun; 2020 Mar; 11(1):1310. PubMed ID: 32161258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Organoid cultures of early-onset colorectal cancers reveal distinct and rare genetic profiles.
    Yan HHN; Siu HC; Ho SL; Yue SSK; Gao Y; Tsui WY; Chan D; Chan AS; Wong JWH; Man AHY; Lee BCH; Chan ASY; Chan AKW; Hui HS; Cheung AKL; Law WL; Lo OSH; Yuen ST; Clevers H; Leung SY
    Gut; 2020 Dec; 69(12):2165-2179. PubMed ID: 32217638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Organoid Culture of Isolated Cells from Patient-derived Tissues with Colorectal Cancer.
    Xie BY; Wu AW
    Chin Med J (Engl); 2016 Oct; 129(20):2469-2475. PubMed ID: 27748340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plocabulin Displays Strong Cytotoxic Activity in a Personalized Colon Cancer Patient-Derived 3D Organoid Assay.
    Costales-Carrera A; Fernández-Barral A; Bustamante-Madrid P; Guerra L; Cantero R; Barbáchano A; Muñoz A
    Mar Drugs; 2019 Nov; 17(11):. PubMed ID: 31752287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening.
    Broutier L; Mastrogiovanni G; Verstegen MM; Francies HE; Gavarró LM; Bradshaw CR; Allen GE; Arnes-Benito R; Sidorova O; Gaspersz MP; Georgakopoulos N; Koo BK; Dietmann S; Davies SE; Praseedom RK; Lieshout R; IJzermans JNM; Wigmore SJ; Saeb-Parsy K; Garnett MJ; van der Laan LJ; Huch M
    Nat Med; 2017 Dec; 23(12):1424-1435. PubMed ID: 29131160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy.
    Narasimhan V; Wright JA; Churchill M; Wang T; Rosati R; Lannagan TRM; Vrbanac L; Richardson AB; Kobayashi H; Price T; Tye GXY; Marker J; Hewett PJ; Flood MP; Pereira S; Whitney GA; Michael M; Tie J; Mukherjee S; Grandori C; Heriot AG; Worthley DL; Ramsay RG; Woods SL
    Clin Cancer Res; 2020 Jul; 26(14):3662-3670. PubMed ID: 32376656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional Optical Imaging of Primary Human Tumor Organoids: Development of a Personalized Drug Screen.
    Walsh AJ; Cook RS; Skala MC
    J Nucl Med; 2017 Sep; 58(9):1367-1372. PubMed ID: 28588148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRIB3 Interacts With β-Catenin and TCF4 to Increase Stem Cell Features of Colorectal Cancer Stem Cells and Tumorigenesis.
    Hua F; Shang S; Yang YW; Zhang HZ; Xu TL; Yu JJ; Zhou DD; Cui B; Li K; Lv XX; Zhang XW; Liu SS; Yu JM; Wang F; Zhang C; Huang B; Hu ZW
    Gastroenterology; 2019 Feb; 156(3):708-721.e15. PubMed ID: 30365932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic heterogeneity of 2D organoid reflects clinical tumor characteristics.
    Fujino S; Ito A; Ohue M; Yasui M; Mizushima T; Doki Y; Mori M; Miyoshi N
    Biochem Biophys Res Commun; 2019 May; 513(2):332-339. PubMed ID: 30955861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testing Susceptibility of Patient-Derived Organoid Cultures to Therapies: Pharmacotyping.
    Burkhart RA; Baker LA; Tiriac H
    Methods Mol Biol; 2018; 1787():253-261. PubMed ID: 29736724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening.
    Yan HHN; Siu HC; Law S; Ho SL; Yue SSK; Tsui WY; Chan D; Chan AS; Ma S; Lam KO; Bartfeld S; Man AHY; Lee BCH; Chan ASY; Wong JWH; Cheng PSW; Chan AKW; Zhang J; Shi J; Fan X; Kwong DLW; Mak TW; Yuen ST; Clevers H; Leung SY
    Cell Stem Cell; 2018 Dec; 23(6):882-897.e11. PubMed ID: 30344100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors.
    Maru Y; Tanaka N; Itami M; Hippo Y
    Gynecol Oncol; 2019 Jul; 154(1):189-198. PubMed ID: 31101504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer modeling meets human organoid technology.
    Tuveson D; Clevers H
    Science; 2019 Jun; 364(6444):952-955. PubMed ID: 31171691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer research using organoid technology.
    Kretzschmar K
    J Mol Med (Berl); 2021 Apr; 99(4):501-515. PubMed ID: 33057820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling liver cancer and therapy responsiveness using organoids derived from primary mouse liver tumors.
    Cao W; Liu J; Wang L; Li M; Verstegen MMA; Yin Y; Ma B; Chen K; Bolkestein M; Sprengers D; van der Laan LJW; Doukas M; Kwekkeboom J; Smits R; Peppelenbosch MP; Pan Q
    Carcinogenesis; 2019 Mar; 40(1):145-154. PubMed ID: 30289434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Cell and Organoid-Level Analysis of Patient-Derived 3D Organoids to Evaluate Tumor Cell Growth Dynamics and Drug Response.
    Kim S; Choung S; Sun RX; Ung N; Hashemi N; Fong EJ; Lau R; Spiller E; Gasho J; Foo J; Mumenthaler SM
    SLAS Discov; 2020 Aug; 25(7):744-754. PubMed ID: 32349587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of 2.5D organoid culture model using 3D bladder cancer organoid culture.
    Abugomaa A; Elbadawy M; Yamanaka M; Goto Y; Hayashi K; Mori T; Uchide T; Azakami D; Fukushima R; Yoshida T; Shibutani M; Yamashita R; Kobayashi M; Yamawaki H; Shinohara Y; Kaneda M; Usui T; Sasaki K
    Sci Rep; 2020 Jun; 10(1):9393. PubMed ID: 32523078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studying cellular heterogeneity and drug sensitivity in colorectal cancer using organoid technology.
    Sasaki N; Clevers H
    Curr Opin Genet Dev; 2018 Oct; 52():117-122. PubMed ID: 30261425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 122.